Clinical trials: Transplantation, Corneal
Corneal Neovascularization, Corneal Graft Failure
A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival
The goal of this study is to investigate whether using bevacizumab (Avastin®) is both safe and effective at decreasing the likelihood of a high-risk corneal graft rejection.
- Trial name
- NCT01996826
- Testing
- Avastin® (bevacizumab), 0.9% NaCl & Refresh Liquigel
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- Reza Dana, MD
Keratoconus
Lamellar Transplant With Lyophilized Corneas
The goals of this study are to develop a lyophilization method for anterior lamellar transplants in Brasil and to make a comparative analysis among patients transplanted with lyophilized and optisol corneas
- Trial name
- NCT00409955
- Testing
- Lamellar transplant with lyophilized corneas
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Federal University of São Paulo
Fuch's Endothelial Dystrophy, Pseudophakic Bullous Keratopathy
Comparison of Corneal Grafts Cultured in Serum-free Versus Corneal Grafts Cultured in Serum Supplemented Culture Media
The goal of this clinical trial is to compare the quality of corneal grafts cultured in a serum-free culture medium with a defined composition versus corneal grafts cultured in a standard serum supplemented culture medium…
- Trial name
- SFM (NCT00623584)
- Testing
- Corneal transplantation
- Where
- 2 sites in Germany
- Volunteers
- 60 people
- Sponsor
- Klinikum Chemnitz gGmbH
Corneal Transplant Rejection
Risk Factors for Human Corneal Graft Failure : a Monocentric Retrospective Observational Cohort
Keratoplasty is one of the most common grafts and penetrating keratoplasty is still the technique most used in the world, ahead of lamellar grafts, and is estimated to represent 70% of the total.
- Trial name
- NCT04791696
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Montpellier
Fuchs Endothelial Corneal Dystrophy
Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy
This protocol will investigate whether topical application of N-acetyl cysteine (NAC) eye drops decreases oxidative stress and confers cytoprotection in patients with FECD.
- Trial name
- NCT04440280
- Testing
- N-acetyl cysteine (NAC) 10% solution, N-acetyl cysteine (NAC) 20% solution, Visine Dry Eye Relief eye drops
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Massachusetts Eye and Ear Infirmary